✦ LIBER ✦

3 INVITED Challenges to Implementation of Personalised Cancer Therapy

✍ Scribed by G. Mills

Book ID: 117660715
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 37 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(11)70218-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Overcoming challenges to the implementat

Overcoming challenges to the implementation of antiretroviral therapy in Kenya

✍ Miriam Taegtmeyer; Kenneth Chebet 📂 Article 📅 2002 🏛 The Lancet 🌐 English ⚖ 302 KB

Challenges to implementation of artemisi

Challenges to implementation of artemisinin combination therapy policy in Uganda

✍ Vincent Batwala; Pascal Magnussen; Fred Nuwaha 📂 Article 📅 2010 🏛 Oxford University Press 🌐 English ⚖ 158 KB

237 INVITED Strategies to transfer succe

237 INVITED Strategies to transfer success in the development of molecularly targeted therapy to the challenge of paediatric cancers

✍ P. Workman 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB

418 INVITED Intravital Imaging of Cancer

418 INVITED Intravital Imaging of Cancer Invasion and Resistance to Therapy

✍ P. Friedi 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 36 KB

Challenges and opportunities to the desi

Challenges and opportunities to the design and implementation of chemoprevention trials for prostate cancer

✍ Ian M Thompson; Joseph A Basler; Robin Leach; Dean Troyer; Eric Klein; Otis Braw 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 87 KB

Rational approach to implementation of p

Rational approach to implementation of prostate cancer antigen 3 into clinical care

✍ Rou Wang; Arul M. Chinnaiyan; Rodney L. Dunn; Kirk J. Wojno; John T. Wei 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 1 views

## Abstract ## BACKGROUND: Prostate cancer antigen 3 (__PCA3__) encodes a prostate‐specific messenger ribonucleic acid (mRNA) that serves as the target for a novel urinary molecular assay for prostate cancer detection. The objective of the current study was to evaluate the ability of PCA3, added t